Quell Therapeutics

Tracey Lodie, Ph.D., Chief Scientific Officer

Oct. 11 | 4:00pm | Ecolab Life Sciences Ballroom 

London, UK


Quell Therapeutics Ltd is a leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system. Quell has raised over $300M capital to date from a premier syndicate of life science investors, as well as a strategic partnership with AstraZeneca worth over $2Bn in milestones. Quell’s lead program QEL-001 is currently in phase I/II development in liver transplantation, with the goal of inducing operational tolerance and full immuno-suppression withdrawal to address the unwanted co-morbidities of chronic immunosuppression. Quell is developing preclinical programs in autoimmunity (type 1 diabetes, inflammatory bowel disease), as well as neuroinflammation. Quell is also researching allogenic iPSC derived Tregs through a collaboration with Cellistic.


By using this website you agree to accept our Privacy Policy and Terms & Conditions